Anti-cancer Effects of DHP107 on Canine Mammary Gland Cancer Examined Through In-vitro and In-vivo Mouse Xenograft Models

Overview

Journal BMC Vet Res

Publisher Biomed Central

Specialty Veterinary Medicine

Date 2024 Jan 3

PMID 38172758

Authors

Hyung-Kyu Chae

Ye-In Oh

Ga-Hyun Lim

Yun-Chan Jung

Seol-Hee Park

Ju-Hyun An

Su-Min Park

Kyoung-Won Seo

Sung-Nam Chu

Qiang Li

Hwa-Young Youn

Affiliations

Soon will be listed here.

Abstract

Background: Canine mammary gland cancer (CMGC) is a common neoplasm in intact bitches. However, the benefit of adjuvant chemotherapy is unclear. The aim of this study was to investigate the anti-proliferative effects of paclitaxel on CMGC in in-vitro and in-vivo settings.

Results: Paclitaxel dose-dependently inhibited viability and induced G2/M phase cell cycle arrest and apoptosis in both primary and metastatic CMGC cell lines (CIPp and CIPm). In animal experiments, the average tumour volume decreased significantly in proportion to the administered oral paclitaxel dose. By examining tumour tissue using a TUNEL assay and immunohistochemical staining with anti-CD31 as a marker of endothelial differentiation, respectively, it was confirmed that oral paclitaxel induced apoptosis and exerted an anti-angiogenetic effect in tumour tissues. Further, downregulation of cyclin D1 in tumour tissues suggested that oral paclitaxel induced cell cycle arrest in tumour tissues in-vivo.

Conclusions: Our results suggest that paclitaxel may have anti-cancer effects on CMGC through cell cycle arrest, induction of apoptosis, and anti-angiogenesis. This study could provide a novel approach to treat CMGC.

References

Simon D, Schoenrock D, Baumgartner W, Nolte I . Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J Vet Intern Med. 2006; 20(5):1184-90. DOI: 10.1892/0891-6640(2006)20[1184:patimm]2.0.co;2. View

Kang Y, Ryu M, Park S, Kim J, Kim J, Cho S . Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann Oncol. 2018; 29(5):1220-1226. DOI: 10.1093/annonc/mdy055. View

Jensen M, Jorgensen J, Binderup T, Kjaer A . Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging. 2008; 8:16. PMC: 2575188. DOI: 10.1186/1471-2342-8-16. View

Marconato L, Lorenzo R, Abramo F, Ratto A, Zini E . Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs. Vet Comp Oncol. 2009; 6(2):90-101. DOI: 10.1111/j.1476-5829.2007.00143.x. View

Sharifi-Rad J, Quispe C, Patra J, Singh Y, Panda M, Das G . Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy. Oxid Med Cell Longev. 2021; 2021:3687700. PMC: 8545549. DOI: 10.1155/2021/3687700. View

Zhang X, Ding Y, Chen J, Xiao X, Zhang W, Zhou L . Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules. J Ethnopharmacol. 2020; 261:113067. DOI: 10.1016/j.jep.2020.113067. View

Bae J, Kim Y, Chae H, Kim D, Choi H, Chin Y . Korean red ginseng extract enhances paclitaxel distribution to mammary tumors and its oral bioavailability by P-glycoprotein inhibition. Xenobiotica. 2016; 47(5):450-459. DOI: 10.1080/00498254.2016.1182233. View

Khanna C, Rosenberg M, Vail D . A Review of Paclitaxel and Novel Formulations Including Those Suitable for Use in Dogs. J Vet Intern Med. 2015; 29(4):1006-12. PMC: 4895360. DOI: 10.1111/jvim.12596. View

Millar E, Dean J, McNeil C, OToole S, Henshall S, Tran T . Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene. 2009; 28(15):1812-20. PMC: 3073345. DOI: 10.1038/onc.2009.13. View

10.

Goldschmidt M, Pena L, Rasotto R, Zappulli V . Classification and grading of canine mammary tumors. Vet Pathol. 2011; 48(1):117-31. DOI: 10.1177/0300985810393258. View

11.

Sorenmo K, Rasotto R, Zappulli V, Goldschmidt M . Development, anatomy, histology, lymphatic drainage, clinical features, and cell differentiation markers of canine mammary gland neoplasms. Vet Pathol. 2010; 48(1):85-97. DOI: 10.1177/0300985810389480. View

12.

Jang Y, Chung H, Hong J, Yun C, Chung H . Absorption mechanism of DHP107, an oral paclitaxel formulation that forms a hydrated lipidic sponge phase. Acta Pharmacol Sin. 2016; 38(1):133-145. PMC: 5220538. DOI: 10.1038/aps.2016.105. View

13.

Hong J, Lee I, Kwak Y, Park Y, Sung H, Kwon I . Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation. Mol Cancer Ther. 2007; 6(12 Pt 1):3239-47. DOI: 10.1158/1535-7163.MCT-07-0261. View

14.

Silva D, Franciosi A, Pezzini P, Guerios S . Subcutaneous administration of paclitaxel in dogs with cancer: A preliminary study. Can Vet J. 2015; 56(8):823-30. PMC: 4502849. View

15.

Sofias A, Dunne M, Storm G, Allen C . The battle of "nano" paclitaxel. Adv Drug Deliv Rev. 2017; 122:20-30. DOI: 10.1016/j.addr.2017.02.003. View

16.

Tran C, Moore A, Frimberger A . Surgical treatment of mammary carcinomas in dogs with or without postoperative chemotherapy. Vet Comp Oncol. 2014; 14(3):252-62. DOI: 10.1111/vco.12092. View

17.

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J . Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol. 2000; 18(1):102-5. DOI: 10.1200/JCO.2000.18.1.102. View

18.

Inglebert M, Dettwiler M, Hahn K, Letko A, Drogemuller C, Doench J . A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer. Sci Rep. 2022; 12(1):18051. PMC: 9614008. DOI: 10.1038/s41598-022-21706-2. View

19.

Shoji K, Yoneda M, Fujiyuki T, Amagai Y, Tanaka A, Matsuda A . Development of new therapy for canine mammary cancer with recombinant measles virus. Mol Ther Oncolytics. 2016; 3:15022. PMC: 4782952. DOI: 10.1038/mto.2015.22. View

20.

Uyama R, Nakagawa T, Hong S, Mochizuki M, Nishimura R, Sasaki N . Establishment of four pairs of canine mammary tumour cell lines derived from primary and metastatic origin and their E-cadherin expression. Vet Comp Oncol. 2009; 4(2):104-13. DOI: 10.1111/j.1476-5810.2006.00098.x. View